The GLP-1 therapy landscape is evolving rapidly, with emerging GLP-1 therapies like amylin analogues and Retatrutide offering new possibilities for weight loss. STAAR LABS is at the forefront of this research, exploring synergistic approaches to enhance outcomes.
Emerging GLP-1 Therapies: Amylin Analogues and Triple-Agonists
- Semaglutide + Amylin (CagriSema): In clinical trials, co-administered semaglutide 2.4 mg and cagrilintide 2.4 mg (a long-acting amylin analogue) achieved 15.6-17.1% weight loss (32-35 lbs) over 32 weeks in type 2 diabetes patients. Cagrilintide enhances satiety and slows gastric emptying, complementing GLP-1’s effects.
- Retatrutide (Triple-Agonist): Developed by Eli Lilly, Retatrutide targets GLP-1, GIP, and glucagon receptors. In Phase 2 trials, it achieved up to 24.2% weight loss (58 lbs) over 48 weeks in adults with obesity, surpassing tirzepatide (22.5%) and semaglutide (15-17%). Currently in Phase 3 trials (expected completion late 2025), Retatrutide is not yet FDA-approved and cannot be legally compounded, but it represents a promising future option for weight loss.*
- Other Amylin Analogues: Pramlintide, an FDA-approved amylin analogue for diabetes, achieves up to 7.9% weight loss. Newer analogues like cagrilintide (6-10.8% weight loss standalone) are in development.
STAAR LABS’ Research: Exploring Synergistic Solutions
STAAR LABS is collaborating with cutting edge clinicians and other partners on a joint research project to advance GLP-1 therapy outcomes.*
- SLM+ Gen 1: The current formula may support 11-15 lbs of weight loss standalone and may enhance GLP-1 therapy outcomes.
- SLM+ Gen 2 (In Development): Expected late Q3 2025. Preliminary projections suggest it may support enhanced outcomes, with full results expected in late 2025.*
- Amylin Research: STAAR LABS is investigating amylin analogues like pramlintide, which may enhance satiety and stabilize blood sugar, potentially adding 5-12 lbs of weight loss when paired with GLP-1 therapies.*
Collaborate with STAAR LABS
STAAR LABS welcomes partnerships with pharmacies and providers to explore similar synergistic protocols. Contact us at info@staarlabs.com to learn more about collaboration opportunities.
Learn how amylin analogues and SLM+ can enhance GLP-1 therapy outcomes in our final post. Join our community to stay up to date with our research.
Legal Disclaimer: These statements have not been evaluated by the Food and Drug Administration (FDA). The information provided is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. SLM+ Gen 2 and Retatrutide are in development and not yet available; projected benefits are subject to change pending final results (expected June 2025 for SLM+ Gen 2, late 2025 for Retatrutide). Always consult a healthcare provider before starting any new therapy or supplement, especially if using GLP-1 therapies or managing medical conditions. STAAR LABS is not responsible for adverse effects resulting from use.
